Organization & Developments: Progenics

Parents

*Organization & Developments: Progenics (Archives 2015-2017)
2018: Biotech Analysis Central Preview Series: Progenics Pharmaceuticals_seekingalpha.com
2018: Progenics Earnings: Get Ready For A Massive Moveseekingalpha.com
2018: Progenics Pharmaceuticals: Don't Worry About Azedra's PDUFA Delay_seekingalpha.com
2018: Progenics Scores A Win In Artificial Intelligence_seekingalpha.com
2018: Progenics Sells Off Again As Another Trial Shows Mixed Results - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2018: Progenics Talks Commercialization, Pipeline, And Milestones_seekingalpha.com
2018: Progenics: Is The SPA Limited To 2 Doses? - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2018: Progenics: This Is Just The Beginning_seekingalpha.com
2018: The Prognosis For Progenics
2018: What's Upcoming For Progenics Pharmaceuticals? - Bret Jensen
2018: Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
2019: Progenics: Joining The Tired Ranks Of Investors_seekingalpha.com
2019: Progenics: Why I Finally Decided To Buy
2019: VA_65--Progenics Pharmaceuticals, Inc. DBA Progenics Pharmaceutical 65IB Drugs, Pharmaceuticals and Hematology related products Contract Award 06/15/2019 to 06/14/2024
An oral formulation of the drug is currently in the late stages of development.
Injectable drug used to treat opioid-induced constipation.